Tech2 Nov 2026
Anthropic Expands Claude Into Drug Discovery to Tackle Clinical and Operational Bottlenecks
Anthropic has escalated its ambitions in biopharma by deploying its Claude AI models directly into active drug programs and acquiring early-stage biotech assets. Partnering with major pharmaceutical organizations and operating its own molecular biology laboratory, the company aims to move beyond molecular design into overcoming administrative, chemical, and operational bottlenecks. While early preclinical results show substantial gains in trial preparation and antibody optimization, researchers caution that human safety trials remain a formidable constraint.
By NeuraFeed
Tech21 Okt 2026
OpenAI Acquires Orchestra Bio to Expand Drug Development Capabilities
OpenAI has acquired biotech software startup Orchestra Bio to integrate agentic operational tools into its Rosalind life sciences ecosystem. The deal allows OpenAI to move beyond laboratory reasoning models into the complex project tracking and workflow orchestration required to bring pharmaceuticals to market. Financial terms were not made public as artificial intelligence labs intensify competition across biological research.
By NeuraFeed
Tech8 Agu 2026
AI Designs Novel Viruses, Sparking Biosecurity Alarms and Medical Hope
Scientists at Stanford University and the Arc Institute have successfully used AI to design 16 new, functional bacteriophages, marking the first time AI has created complete viral genomes. While these AI-generated viruses currently target bacteria and offer promise for combating antibiotic-resistant infections, the breakthrough has ignited urgent biosecurity concerns regarding the potential for misuse and the lack of regulatory frameworks for such rapidly advancing technology. Experts warn that the ability to compose viral genomes using generative AI now exists, but the governance to safely steer it does not.
By NeuraFeed